Event-Driven Stocks

Horizon Therapeutics Public Ltd Co

Healthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕

Signs● 4 gooddetails ↓

Financials

SEC XBRL · annual
 FY22FY21FY20FY19FY18FY17
Revenue$3.63B$3.23B$2.20B$1.30B$1.21B$1.06B
Operating income$617.4M$543.1M$490.0M$126.6M$37.9M−$339.5M
Net income$521.5M$534.5M$389.8M$573.0M−$38.4M−$350.1M
Total assets$9.11B$8.68B$6.07B$4.44B$3.94B$4.20B
Total liabilities——————
Equity$5.07B$4.67B$4.03B$2.19B$1.19B$1.10B
EPS (diluted)$2.22$2.27$1.81$2.90$-0.23$-2.15
Shares out.229.2M224.0M189.9M169.6M164.6M162.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2022
Operating margin
17.0%
Net margin
14.4%
Return on equity
10.3%
Return on assets
5.7%
Return on capital (ROCE)
7.6%
Liabilities / assets
—
Debt / equity
—
Book value / share
$22.13
Revenue growth (YoY)
12.5%
Net income growth (YoY)
−2.4%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2022
Accruals / assets
−8.1%clean
Piotroski F-Score
6/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
77
/ 100
Profitability 100Growth 50Catalyst 33Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 4 good
  • Operating margin is positive
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
0 acquisitions12 disposalsnet −473,744 shares · last 12
InsiderDateTypeSharesPrice
Watkins ThomasDirectorOct 6, 2023D110,447$116.50
Mahony SusanDirectorOct 6, 2023D9,345$116.50
Witz PascaleDirectorOct 6, 2023D25,672$116.50
Grey Michael GDirectorOct 6, 2023D39,361$116.50
Daniel William FDirectorOct 6, 2023D31,915$116.50
Himawan JeffDirectorOct 6, 2023D44,546$116.50
Shannon James SamuelDirectorOct 6, 2023D33,156$116.50
Santini GinoDirectorOct 6, 2023D100,959$116.50
Mcilvenny PatrickOfficer — Chief Accounting OfficerOct 6, 2023D6,874$116.50
Pasternak AndyOfficer — EVP, Chief Strategy OfficerOct 6, 2023D56,338$116.50
Thompson Elizabeth H.Z.Officer — EVP, Research &amp; DevelopmentOct 6, 2023D14,575$116.50
Cox AaronOfficer — EVP, Chief Financial OfficerOct 6, 2023D556$116.50

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (5)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.